ScreenerHero

PBM Psyence Biomedical Ltd.

NAS · US · Healthcare · Biotechnology · psyencebiomed.com
4.880USD-2.79%Mkt Cap: 18.61M $P/E: —

Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap18.61M USD
Enterprise Value11.70M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-6.94M USD
Revenue/Share—
Last Price4.880 USD
Fiscal Year EndMar 2026
MR QuarterMar 2026
Employees12
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-1.88
EV/Revenue—
P/S—
P/B0.68
EPS (TTM)-12.56
EPS (Forward)—
52W Range
1.9202% of range175.78
52W High175.78 USD
52W Low1.920 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-40.94%
ROA-39.48%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.14M USD
CapEx (TTM)500.23K USD
FCF Margin—
FCF Yield-26.62%
Net Debt-7.44M USD
Net Debt/EBITDA1.19
Balance Sheet
Debt/Equity—
Current Ratio14.62
Quick Ratio12.12
Book Value/Sh7.39 USD
Cash/Share1.95 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split16:100
Split DateFeb 2, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.3.81M
Float2.61M
Insiders2.97%
Institutions9.66%
Short Interest
Short Ratio0.5d
Short % Float1.81%
Short % Out.1.26%
Shares Short48.22K
Short (prev mo.)14.38K
Technical
SMA 504.536 (+7.6%)
SMA 2007.127 (-31.5%)
Beta1.69
S&P 52W Chg15.78%
Avg Vol (30d)101.47K
Avg Vol (10d)104.72K
Technical Indicators
RSI (14)47.7
MACD0.2409
MACD Signal0.4116
MACD Hist.-0.1706
BB Upper6.714 USD
BB Middle5.391 USD
BB Lower4.067 USD
BB Width49.11%
ATR (14)0.4787 USD
Vol Ratio (20d)0.20x